MetaCap

Amylyx Pharmaceuticals Inc. Company Profile

NASDAQ: AMLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

26.02-0.18 (-0.69%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Amylyx Pharmaceuticals at a glance

Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Cambridge, MA. Amylyx Pharmaceuticals is led by Mr. Joshua B. Cohen and employs about 136 people. The company's shares have traded publicly since 2022.

At a market capitalization of $3.37 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001658551, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Amylyx Pharmaceuticals do?

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Amylyx Pharmaceuticals Inc.
Ticker
NASDAQ: AMLX
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Joshua B. Cohen
Employees
136
Headquarters
55 Cambridge Parkway, Cambridge, MA, United States
Phone
617 682 0917
Website
amylyx.com
IPO year
2022
SEC CIK
0001658551
Latest annual report
10-K · Mar 3, 2026

Companies similar to Amylyx Pharmaceuticals

AMLX peer companies
CompanyPrice% ChgMarket capCompare
VRDNViridian Therapeutics Inc.29.96-4.71%$3.40Bvs AMLX
ARQTArcutis Biotherapeutics Inc.26.36-2.98%$3.33Bvs AMLX
IRONDisc Medicine Inc.75.14-1.27%$3.42Bvs AMLX
ELVNEnliven Therapeutics Inc.46.53+0.26%$3.42Bvs AMLX
PBLSParabilis Medicines Inc.27.44-0.67%$3.44Bvs AMLX
ABCLAbCellera Biologics Inc.9.69-7.45%$3.16Bvs AMLX
VKTXViking Therapeutics Inc.24.77-4.14%$3.16Bvs AMLX
XERSXeris Biopharma Holdings Inc.16.97+2.11%$3.10Bvs AMLX

Related